Tokyo, Japan, May 7, 2025 – APRINOIA Therapeutics Inc. (“APRINOIA”), a clinical-stage biopharmaceutical company, is pleased to announce a new service for HMWoTau measurements for research institutions and companies engaged in pathophysiological research and drug/diagnostics development targeting tau proteins.

This service is based on our research technology of high-molecular-weight oligomeric tau (HMWoTau) ELISA systems using our monoclonal antibody APNmAb005. (For more details, see this paper published in The FASEB Journal in 2024.) We believe that the HMWoTau species plays a key role in the progression of tau-associated neurodegenerative diseases.

APRINOIA welcomes research institutions, biotech companies, and pharmaceutical companies tackling tauopathies such as Alzheimer’s Diseases to leverage our new service. See https://aprinoia.com/hmwotau-elisa/ for information describing our service in more detail and to request a quote. You can also contact us directly via email at HMWoTauELISAservice@aprinoia.com, where our team of specialists will reach out to you.  

About APRINOIA

APRINOIA Therapeutics Inc. is a clinical-stage biotechnology company, headquartered in Tokyo, Japan, committed to developing highly sensitive and selective diagnostic and highly effective therapeutic agents for a broad range of neurodegenerative diseases, including Alzheimer’s disease and Parkison’s disease. To learn more, please visit https://aprinoia.com/ and follow us on LinkedIn.